Dr Leary on the FDA Approval of Tovorafenib for Pediatric R/R BRAF+ Low-Grade Glioma


Sarah E. S. Leary, MD, MS, discusses the FDA approval of tovorafenib for pediatric patients with relapsed/refractory, BRAF-mutant low-grade glioma.

Sarah E. S. Leary, MD, MS, attending physician, medical director, Pediatric Brain Tumor Program, Seattle Children’s Hospital; professor, Department of Pediatrics, University of Washington School of Medicine, discusses the significance of the FDA approval of tovorafenib (Ojemda) for pediatric patients with relapsed/refractory, BRAF-mutant low-grade glioma.

On April 23, 2024, the FDA granted accelerated approval to tovorafenib for the treatment of pediatric patients 6 months of age or older who have relapsed/refractory low-grade glioma with a BRAF fusion, a BRAF rearrangement, or a BRAF V600 mutation. This regulatory decision was based on findings from the single-arm, multicenter, open-label, phase 2 FIREFLY-1 trial (NCT04775485), in which the agent elicited an overall response rate per Response Assessment in Pediatric Neuro-Oncology Low-Grade Glioma criteria of 51% (95% CI, 40%-63%) among 76 pediatric patients with relapsed/refractory low-grade glioma harboring an activating BRAFalteration who had prior exposure to at least 1 line of systemic therapy. Furthermore, the median duration of response was 13.8 months (95% CI, 11.3–not estimable). Patients received the agent once per week at doses ranging from 290 mg/m2 to 476 mg/m2, up to a maximum dose of 600 mg, according to body surface area. The recommended dose of tovorafenib based on body surface area is 380 mg/m2 once weekly, with a maximum recommended dose of 600 mg once weekly.

Low-grade glioma is the most common pediatric tumor, Leary says. Although low-grade glioma is described as a benign tumor, Leary cautions against considering this disease benign. Glioma is a brain tumor, and the brain is crucial and central to many human functions, Leary emphasizes. Furthermore, low-grade glioma may be life threatening for some patients, Leary explains.

Prior to the approval of tovorafenib, no FDA-approved medical therapies existed for patients with pediatric low-grade glioma, Leary notes. Tovorafenib was the first drug in this indication to be considered for approval by the FDA and is therefore the first FDA-approved therapy for this patient population, Leary concludes.

Related Videos
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD
Sumanta Kumar Pal, MD, FASCO,
Carrie L. Kitko, MD
Kara N. Maxwell, MD, PhD
Kian-Huat Lim, MD, PhD
Thomas F. Gajewski, MD, PhD
Michelle Krogsgaard, PhD
Lori A. Leslie, MD